Please ensure Javascript is enabled for purposes of website accessibility

Johnson & Johnson Given Control of Emergent BioSolutions Factory That Botched Its Coronavirus Vaccine

By Eric Volkman - Apr 5, 2021 at 7:51PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The move follows errors in the production of a batch of Johnson & Johnson's jab.

The U.S. government has given Johnson & Johnson (JNJ 1.75%) control of a Baltimore production facility operated by Emergent BioSolutions (EBS 11.49%).

The move is the latest development in a controversy over Emergent's production of Johnson & Johnson's coronavirus vaccine, the latest of three to receive Emergency Use Authorization from the Food and Drug Administration. Last week, Emergent admitted that it manufactured a batch of the vaccine in the Baltimore facility that "did not meet specifications and our rigorous quality standards."

Man receiving a vaccination shot.

Image source: Getty Images.

According to various media reports, the company mixed up components of the coronavirus vaccines made by Johnson & Johnson and its rival, AstraZeneca. All told, the offending batch was equivalent to roughly 15 million doses of vaccine; Johnson & Johnson has promised to deliver 100 million by the end of next month.

Emergent disposed of the Johnson & Johnson batch, but its reputation suffered, particularly given the high degree of importance in producing coronavirus vaccines. While the pace of vaccinations has increased significantly in the U.S., the coronavirus is still a major health threat in the country, and barely over 30% of Americans have had at least one shot.

This is compounded by the fact that, of the three authorized vaccines, only Johnson & Johnson's is a single-jab solution, as opposed to a shot-and-booster regime.

Quoted by National Public Radio, Johnson & Johnson said of its new responsibility as the Emergent facility's manager that it will boost "the number of manufacturing, quality and technical operations personnel to work with the Company specialists already at Emergent."

On Monday, Johnson & Johnson stock closed 0.4% higher, lagging the 1.4% gain of the S&P 500 index. Emergent, still somewhat of a pariah due to the mishap, fell by 2.3%.


Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Johnson & Johnson Stock Quote
Johnson & Johnson
$176.98 (1.75%) $3.04
Emergent BioSolutions Inc. Stock Quote
Emergent BioSolutions Inc.
$35.33 (11.49%) $3.64

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/22/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.